Project Grant R01NS138167
- This Project Grant award of $374,349 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the development and optimization of a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The goal is to create a mouse model that accurately recapitulates the human disease spectrum by incorporating an acetylation-mimicking...
- This Project Grant award of $387,525 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to investigate the role of proton-mediated signaling at the neuromuscular junction in amyotrophic lateral sclerosis (ALS) models. The research aims to study how dysregulation of extracellular proton (pH) concentrations may contribute to the progression of ALS in...
- This Project Grant award of $532,381 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research into the pathogenic mechanisms of the KIF5A gene mutation associated with amyotrophic lateral sclerosis (ALS). The key objectives of this 5-year research project are to: 1) determine the gain-of-function effects of the ALS-associated KIF5A exon 27 skipping variant...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
- This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, consolidates multiple research projects into a single larger R35 grant to enable comprehensive exploration of biological mechanisms underlying neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson's disease. The...
- This Project Grant award of $129,717 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate the role of neutrophils in the pathology of amyotrophic lateral sclerosis (ALS). The research, conducted by the Regents of the University of Michigan, aims to identify neutrophil subpopulations and mechanisms associated with ALS progression and...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $645,391 to The Trustees of Columbia University in the City of New York to conduct research on the effects of re-expressing embryonic motor neuron selector transcription factors in mouse models of amyotrophic lateral sclerosis (ALS) and in ALS motor neurons derived from induced...
- This Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), aims to develop advanced base and prime editing strategies to correct common ALS-causing mutations in the SOD1 gene. The $124,246 award, granted to the University of Massachusetts Medical School, will support in vitro and in vivo studies to create next-generation base and prime editors for...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,499,212 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Aquinnah Pharmaceuticals, Inc. The grant supports the development of a novel oral, brain penetrant therapeutic to slow and potentially reverse the progression of Amyotrophic Lateral Sclerosis (ALS). The key product being delivered is an innovative new clinical drug candidate designed to...
- This Project Grant award of $426,313, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), supports research at The Johns Hopkins University to investigate the signaling pathways that disrupt neurofilament (NF) phosphorylation dynamics and lead to NF hyperphosphorylation, a pathology associated with neurodegenerative diseases such as amyotrophic lateral...
This federal Project Grant award of $592,233.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research on the regulation of sphingolipid biosynthesis and its relationship to amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. The research will utilize cellular models and mouse models to investigate how mutations in the serine palmitoyltransferase (SPT) enzyme, which catalyzes the first step in sphingolipid biosynthesis, lead to disruptions in mitochondrial function and increased ceramide content, potentially contributing to motor neuron degeneration in ALS. The research aims to enhance understanding of the metabolic causes of ALS and identify potential therapeutic targets.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $592.2k | 8/1/25 |